Tag results:
induced pluripotent stem cells
ESC & iPSC News
Specific Mesoderm Subset Derived from Human Pluripotent Stem Cells Ameliorates Microvascular Pathology in Type 2 Diabetic Mice
[Science Advances] Transcriptomic analysis showed that differentiation of hiPSCs derived from diabetics into KDR+CD56+APLNR+ (KNA+) cells was sufficient to change baseline differences in gene expression caused by the diabetic status and reprogram diabetic cells to a pattern similar to KNA+ cells derived from nondiabetic hiPSCs.
ESC & iPSC News
One-Step Induction of Photoreceptor-Like Cells from Human iPSCs by Delivering Transcription Factors
[iScience] Scientists developed a method to generate photoreceptor cells (PRCs) from human iPSCs by introducing the transcription factors CRX and NEUROD1, which enabled them to generate induced photoreceptor-like cells (iPRCs) expressing PRC markers.
ESC & iPSC News
Human Induced Pluripotent Stem Cells Integrate, Create Synapses and Extend Long Axons after Spinal Cord Injury
[Journal of Cellular and Molecular Medicine] The authors transplanted cells that were generated from hiPSCs into regionally specific spinal neural progenitor cells utilizing a novel accelerated differentiation protocol designed for clinical translation.
ESC & iPSC News
Analyses of Erythropoiesis from Embryonic Stem Cell-CD34+ and Cord Blood-CD34+ Cells Reveal Mechanisms for Defective Expansion and Enucleation of Embryomic Stem Cell-Erythroid Cells
[Journal of Cellular and Molecular Medicine] Investigators found that the limited expansion of ESC CD34+ cell-derived erythroid cells was associated with defective cell cycle of erythroid progenitors.
ESC & iPSC News
Doxorubicin Induces Cardiotoxicity in a Pluripotent Stem Cell Model of Aggressive B Cell Lymphoma Cancer Patients
[Basic Research in Cardiology] Researchers established an in vitro iPSC model of anthracycline-induced cardiotoxicity (ACT) from patients with an aggressive form of B-cell lymphoma and examined whether doxorubicin-treated ACT-iPSC cardiomyocytes could recapitulate the clinical features exhibited by patients.
ESC & iPSC News
Alchemab Extends Partnership with Medicines Discovery Catapult to Bolster Collaborative Approach to Tackle Alzheimer’s Disease
[Alchemab Therapeutics] Alchemab Therapeutics, a biotechnology company focused on the discovery and development of naturally-occurring protective antibodies in neurodegeneration and oncology, announced an extension of its collaboration with Medicines Discovery Catapult, a national facility enabling the UK’s community to accelerate innovative drug discovery.